Amryt Pharma PLC Notice of Results (8035Y)
08 March 2017 - 6:01PM
UK Regulatory
TIDMAMYT
RNS Number : 8035Y
Amryt Pharma PLC
08 March 2017
AIM: AMYT, ESM: AYP
Amryt Pharma plc
("Amryt" or the "Company")
Date of Results
Amryt, the pharmaceutical company focused on best-in-class
treatments for rare and orphan diseases, announces that results for
the financial year to 31 December 2016 are expected to be reported
on Thursday, 30 March 2017.
Enquiries:
c/o KTZ Communications
Amryt Pharma plc +44 (0)20 3178 6378
Joe Wiley, CEO
Rory Nealon, CFO/COO
Shore Capital +44 (0) 20 7408 4090
Nomad and Joint Broker
Bidhi Bhoma, Edward Mansfield
Davy +353 (1) 679 6363
ESM Adviser and Joint Broker
John Frain, Anthony Farrell
Stifel +44 (0) 20 7710 7600
Joint Broker
Jonathan Senior, Ben Maddison
KTZ Communications +44 (0) 20 3178 6378
Katie Tzouliadis, Emma Pearson
About Amryt Pharma plc - see www.amrytpharma.com
Amryt Pharma is a specialty pharmaceutical company focused on
developing and delivering innovative new treatments to help improve
the lives of patients with rare or orphan diseases. The Company is
building a diversified portfolio of commercially attractive,
best-in-class, proprietary new drugs to help address some of these
rare and debilitating illnesses for which there are currently no
available treatments.
The Company recently acquired an exclusive licence to sell
LOJUXTA (lomitapide), across the EU and other territories including
the Middle East, North Africa, Turkey and Israel. LOJUXTA is used
to treat a rare life-threatening disease called Homozygous Familial
Hypercholesterolemia.
Amryt's lead development product, AP101 (Episalvan), received
marketing approval for the treatment of partial-thickness wounds
from the European Commission in January 2016. Amryt intends to
develop AP101 (Episalvan) as a new treatment for Epidermolysis
Bullosa ("EB"), a rare and distressing genetic skin disorder
affecting young children for which there is currently no treatment.
The Company is currently planning a Phase 3 study of AP101
(Episalvan) in EB, which has been granted US and EU orphan drug
designation. The global market opportunity for EB is estimated to
be circa EUR 1.3 billion.
Amryt's earlier stage product AP102 is focused on developing
novel, next generation somatostatin analogue ("SSA") peptide
medicines for patients with rare neuroendocrine diseases, where
there is a high unmet medical need, including acromegaly and
Cushing's disease. AP102 was recently granted orphan designation in
the US in acromegaly by the FDA.
The Company joined AIM and Dublin's ESM in April 2016 following
the reverse takeover of Fastnet Equity PLC.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NORSSEEFWFWSELD
(END) Dow Jones Newswires
March 08, 2017 02:01 ET (07:01 GMT)
Amryt Pharma (LSE:AMYT)
Historical Stock Chart
From Apr 2024 to May 2024
Amryt Pharma (LSE:AMYT)
Historical Stock Chart
From May 2023 to May 2024